Relationship between direct-to-consumer advertising and physician diagnosing and prescribing

被引:44
|
作者
Zachry, WM
Shepherd, MD
Hinich, MJ
Wilson, JP
Brown, CM
Lawson, KA
机构
[1] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA
[2] Univ Arizona, Coll Pharm, Ctr Pharmacoecon & Outcomes Res, Tucson, AZ 85721 USA
[3] Univ Texas, Coll Pharm, Pharm Adm Div, Austin, TX 78712 USA
[4] Univ Texas, Coll Pharm, Ctr Pharmacoecon Studies, Austin, TX 78712 USA
[5] Univ Texas, Coll Pharm, Dept Govt, Austin, TX 78712 USA
关键词
advertising; costs; industry; pharmaceutical; marketing; physicians; prescribing; prescriptions;
D O I
10.1093/ajhp/59.1.42
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The relationships between direct-to-consumer advertising expenditures and the monthly frequencies of diagnoses and prescriptions written associated with the products advertised are examined. The analyses utilized quasi-experimental time-series techniques. Data from the National Ambulatory Medical Care Survey and Competitive Media Reporting were used to calculate monthly levels of the dependent and independent variables. The dependent variables included monthly frequencies of diagnoses for the products' FDA-approved indications, medications prescribed within the advertised pharmaceutical class, and medications prescribed for the specific advertised agent. The independent variables included monthly expenditures for advertising each pharmaceutical class and each specific agent. Several significant monthly relationships were found. The diagnoses of hyperlipidemia (P = 0.008) and the number of prescriptions written for antilipemics (p = 0.003) were positively associated with the advertising expenditure for antilipemics. The number of prescriptions written for Claritin (p = 0.004) and Zocor (p < 0.001) was positively related to the advertising expenditure for their respective pharmaceutical classes; the amount of prescriptions written for Hismanal (p = 0.007), Seldane (p < 0.001), and Zantac (p = 0.004) was negatively related to the advertising expenditure for their respective pharmaceutical classes. The number of prescriptions written for Claritin (p = 0.005) and Zocor (p < 0.001) was positively related to the advertising expenditure for each specific product; the amount of prescriptions written for Hismanal (P = 0.049) was negatively associated with the amount of money spent specifically advertising the agent. No significant associations were found in anti hypertensive drugs and drugs to treat benign prostatic hypertrophy. The results of the analyses suggest that the direct-to-consumer advertising expenditure is associated with physician diagnosing and physician prescribing for certain drugs and drug classes.
引用
收藏
页码:42 / 49
页数:8
相关论文
共 50 条
  • [21] Direct-to-Consumer Pharmaceutical Advertising
    DeLeo, Vincent A.
    [J]. CUTIS, 2016, 97 (01): : 10 - 11
  • [22] Direct-to-consumer advertising in oncology
    Abel, Gregory A.
    Penson, Richard T.
    Joffe, Steven
    Schapira, Lidia
    Chabner, Bruce A.
    Lynch, Thomas J., Jr.
    [J]. ONCOLOGIST, 2006, 11 (02): : 217 - 226
  • [23] Models of Physician-Patient Relationships in Pharmaceutical Direct-to-Consumer Advertising and Consumer Interviews
    Arney, Jennifer
    Lewin, Benjamin
    [J]. QUALITATIVE HEALTH RESEARCH, 2013, 23 (07) : 937 - 950
  • [24] Direct-to-consumer advertising of COX-2 inhibitors: Effect on appropriateness of prescribing
    Spence, MM
    Teleki, SS
    Cheetham, TC
    Schweitzer, SO
    Millares, M
    [J]. MEDICAL CARE RESEARCH AND REVIEW, 2005, 62 (05) : 544 - 559
  • [25] Effects of Direct-To-Consumer Advertising on Patient Prescription Requests and Physician Prescribing: A Systematic Review of Psychiatry-Relevant Studies
    Becker, Sara J.
    Midoun, Miriam M.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 (10) : E1293 - E1300
  • [26] Physician Assistants' Views of Direct-to-Consumer Advertising Effects During Patient Encounters
    Filipova, Anna A.
    [J]. INTERNET JOURNAL OF ALLIED HEALTH SCIENCES AND PRACTICE, 2020, 18 (02):
  • [27] Physician Exposure to Direct-to-Consumer Pharmaceutical Marketing: Potential for Creating Prescribing Bias
    Brown, Jeffrey L.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2017, 130 (06): : E247 - E248
  • [28] Dangers and Opportunities of Direct-to-Consumer Advertising
    Parekh, Natasha
    Shrank, William H.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 (05) : 586 - 587
  • [29] DIRECT-TO-CONSUMER ADVERTISING OF PRESCRIPTION DRUGS
    NOVITCH, M
    [J]. FOOD AND DRUG LAW JOURNAL, 1984, 39 (03): : 306 - 311
  • [30] Direct-to-consumer advertising: Education or anathema?
    Rosner, F
    Kark, P
    Packer, S
    Bennett, A
    Berger, L
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (13): : 1227 - 1227